Detalhe da pesquisa
1.
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Nature
; 596(7870): 126-132, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34290408
2.
Epigenetic therapy inhibits metastases by disrupting premetastatic niches.
Nature
; 579(7798): 284-290, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32103175
3.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
N Engl J Med
; 386(21): 1973-1985, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403841
4.
Genome-wide cell-free DNA fragmentation in patients with cancer.
Nature
; 570(7761): 385-389, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142840
5.
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
Oncologist
; 29(4): 342-349, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38207008
6.
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Future Oncol
; 19(8): 549-557, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815433
7.
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
Oncologist
; 27(11): 971-981, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35972337
8.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med
; 381(21): 2020-2031, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31562796
9.
Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review.
Ann Hematol
; 101(1): 1-10, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34962580
10.
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(4): 387-405, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390769
11.
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Nature
; 598(7881): E1, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34608287
12.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med
; 378(22): 2093-2104, 2018 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658845
13.
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
N Engl J Med
; 378(21): 1976-1986, 2018 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658848
14.
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.
Ann Rheum Dis
; 79(3): 332-338, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31540935
15.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
J Natl Compr Canc Netw
; 18(3): 230-241, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32135517
16.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Lancet Oncol
; 20(10): 1395-1408, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31422028
17.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 375(19): 1823-1833, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27718847
18.
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.
J Natl Compr Canc Netw
; 17(6): 712-720, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200355
19.
Management of Immunotherapy-Related Toxicities, Version 1.2019.
J Natl Compr Canc Netw
; 17(3): 255-289, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30865922
20.
Pleural fluid secondary to pulmonary cryptococcal infection: a case report and review of the literature.
BMC Infect Dis
; 19(1): 710, 2019 Aug 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31405376